ERBB2 and cancer: Here, we focused on lapatinib, which inhibits both HER2 and EGFR and prevents activation of important downstream pathways, such as ERK/MAPK (extracellular-signal-regulated kinase/mitogen-activated protein kinase) and PI3K (phosphatidylinositol 3-kinase) which can drive cancer progression [6, 7].